Pharmacia & Upjohn 2nd quarter consumer health sales up 77% due to Nicorette, Rogaine.
This article was originally published in The Tan Sheet
PHARMACIA & UPJOHN CONSUMER HEALTHCARE SALES UP 77.4% in the second quarter to $206.8 mil. from $116.6 mil. in the prior-year period "due to the successful introduction of Nicorette gum and the hair regrowth product Rogaine into the U.S. over-the-counter market," the company announced Aug. 5. OTC Nicorette gum is marketed by SmithKline Beecham under a licensing agreement with Pharmacia & Upjohn. Both Rogaine and Nicorette were launched in April
You may also be interested in...
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.